Drug General Information
Drug ID
D0J1WO
Former ID
DCL000548
Drug Name
ISIS 113715
Drug Type
Antisense drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [536259]
Therapeutic Class
Antisense
Company
ISIS
Target and Pathway
Target(s) mRNA of Protein tyrosine phosphatase-1B Target Info [536259], [551054]
KEGG Pathway Adherens junction
Insulin signaling pathway
NetPath Pathway FSH Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
Pathway Interaction Database Insulin Pathway
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Signaling events mediated by PTP1B
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Signaling events mediated by TCPTP
IGF1 pathway
EGF receptor (ErbB1) signaling pathway
Posttranslational regulation of adherens junction stability and dissassembly
PDGFR-beta signaling pathway
N-cadherin signaling events
Reactome Integrin alphaIIb beta3 signaling
Regulation of IFNG signaling
Regulation of IFNA signaling
Growth hormone receptor signaling
WikiPathways Insulin Signaling
Growth hormone receptor signaling
Leptin signaling pathway
Interferon gamma signaling
Interferon alpha/beta signaling
Integrin alphaIIb beta3 signaling
References
Ref 536259Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006;45(8):789-801.
Ref 536259Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006;45(8):789-801.
Ref 551054Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.